scholarly journals Preoperative weight loss with glucagon-like peptide-1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: A longitudinal analysis

2017 ◽  
Vol 20 (3) ◽  
pp. 745-748 ◽  
Author(s):  
Tien Tang ◽  
Sally Abbott ◽  
Carel W. le Roux ◽  
Violet Wilson ◽  
Rishi Singhal ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Bariatric Surgery ◽  
Weight Loss ◽  
Receptor Agonist ◽  
Preoperative Weight Loss ◽  
Preoperative Weight ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Medical Weight Management

Lixisenatide—Once-daily Glucagon-like Peptide-1 Receptor Agonist in the Management of Type 2 Diabetes

2010 ◽  
Vol 8 (1) ◽  
pp. 12 ◽  
Author(s):  
Celeste C L Quianzon ◽  
Mansur E Shomali ◽  
◽  
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Receptor Agonist ◽  
Potential Role ◽  
Glycosylated Haemoglobin ◽  
Once Daily ◽  
Glucagon Suppression ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

The glucagon-like peptide-1 receptor agonist diabetes medications have become important due to their unique features, such as their potency of glycosylated haemoglobin (HbA1C) lowering, durability of effect, glucose-depending insulin secretion resulting in a low risk of hypoglycaemia, glucagon suppression and weight loss. Lixisenatide is an investigational compound in this class, exhibits all of these features, and has some unique properties, which are highlighted in this review. The pharmacology of lixisenatide, the results of recent clinical trials investigating this agent, and its potential role in the management of type 2 diabetes will be discussed.

Lixisenatide—Once-daily Glucagon-like Peptide-1 Receptor Agonist in the Management of Type 2 Diabetes

2011 ◽  
Vol 07 (02) ◽  
pp. 104
Author(s):  
Celeste C L Quianzon ◽  
Mansur E Shomali ◽  
◽  
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Receptor Agonist ◽  
Potential Role ◽  
Glycosylated Hemoglobin ◽  
Once Daily ◽  
Glucagon Suppression ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

The glucagon-like peptide-1 receptor agonist diabetes medications have become important due to their unique features, such as their potency of glycosylated hemoglobin (HbA1C) lowering, durability of effect, glucose-depending insulin secretion resulting in a low risk of hypoglycemia, glucagon suppression, and weight loss. Lixisenatide is an investigational compound in this class, exhibits all of these features, and has some unique properties, which are highlighted in this review. The pharmacology of lixisenatide, the results of recent clinical trials investigating this agent, and its potential role in the management of type 2 diabetes will be discussed.

Sign in / Sign up

Export Citation Format

Share Document